Poester, Vanice RodriguesMunhoz, Lívia SilveiraBenelli, Jéssica LouiseMelo, Aryse MartinsAl-Hatmi, Abdullah M.S.Larwood, David J.Martinez, MarifeStevens, David A.Xavier, Melissa Orzechowski2023-03-162023-03-162022-07-25J Fungi (Basel). 2022 Jul 25;8(8):771. doi: 10.3390/jof80807712309-608Xhttp://hdl.handle.net/10400.18/8551This article belongs to the Special Issue Biology, Immunology, Epidemiology, and Therapy of Fungal Infections: A Themed Issue Dedicated to Professor David A. Stevens.Background: Candida auris is an emergent fungal pathogen and a global concern, mostly due to its resistance to many currently available antifungal drugs. Objective: Thus, in response to this challenge, we evaluated the in vitro activity of potential new drugs, diphenyl diselenide (PhSe)2 and nikkomycin Z (nikZ), alone and in association with currently available antifungals (azoles, echinocandins, and polyenes) against Candida auris. Methods: Clinical isolates of C. auris were tested in vitro. (PhSe)2 and nikZ activities were tested alone and in combination with amphotericin B, fluconazole, or the echinocandins, micafungin and caspofungin. Results: (PhSe)2 alone was unable to inhibit C. auris, and antagonism or indifferent effects were observed in the combination of this compound with the antifungals tested. NikZ appeared not active alone either, but frequently acted cooperatively with conventional antifungals. Conclusion: Our data show that (PhSe)2 appears to not have a good potential to be a candidate in the development of new drugs to treat C. auris, but that nikZ is worthy of further study.engCandida aurisCandida SpeciesAntifungal DrugsChitin Synthase InhibitorDiphenyl Diselenidein vitro Susceptibility AssaysNikkomycin ZOrganoselenium CompoundsInfecções Sistémicas e Zoonosesjournal article10.3390/jof8080771